Showing results (681-690 of 977) with videos related to

Sort By:
Pageof 98
Hepatology (Baltimore, Md.)|September 9, 2022
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trialRyan W Dellinger, Holly E Holmes, Tina Hu-Seliger, et al.
Clinical Chemistry|July 14, 2012
Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndromeChristopher deFilippi, Stephen L Seliger, Walter Kelley, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2001
The discovery of novel, potent and selective PDE5 inhibitorsY Bi, P Stoy, L Adam, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromesJ W Janssen, A C Steenvoorden, J Lyons, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2003
Cardiovascular and thromboembolic events following hypertensive pregnancyBryan Kestenbaum, Stephen L Seliger, Thomas R Easterling, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunctionYingzhi Bi, Patrick Stoy, Leonard Adam, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 20, 2010
Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational studyStephen Seliger, Kathleen M Fox, Shravanthi R Gandra, et al.
Oncotarget|November 20, 2019
Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanomaJohannes Fänder, Heike Kielstein, Maximilian Büttner, et al.
Pageof 98